24 results on '"GELARDI, Teresa"'
Search Results
2. Data from Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
3. Supplementary Figures S1-S2 from Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
4. Supplementary Figure Legend from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
5. Supplementary Figure 4 from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
6. Supplementary Figure 1 from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
7. Supplementary Figure 2 from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
8. EGFR-Directed Monoclonal Antibodies
9. TLR9 Agonist Acts by Different Mechanisms Synergizing with Bevacizumab in Sensitive and Cetuximab-Resistant Colon Cancer Xenografts
10. Mechanisms of resistance to EGFR inhibitors
11. EGFR-Directed Monoclonal Antibodies
12. Enzastaurin inhibits tumors sensitive and resistant to anti-EGFR drugs
13. The mechanisms of resistance to EGFR inhibitors
14. Development of two novel targeted agents as a strategy to overcome the resistance to EGFR inhibitors
15. Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
16. Abstract 5401: The mTOR inhibitor everolimus cooperates with the Toll-like receptor 9 (TLR9) agonist IMO in renal cell carcinoma by interfering with both tumor cells and microenvironment
17. Abstract 615: Novel Toll-like Receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancers
18. A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action
19. Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
20. Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling
21. Rational bases for the development of EGFR inhibitors for cancer treatment
22. Mechanisms of resistance to EGFR inhibitors
23. A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action
24. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.